Zacks.com on MSN2 个月
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet ... However, Bristol Myers’ BMY stock was up ...